Additional file 1 of Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target

Additional file 1: Table S1. Clinicopathological characteristics of patients. Table S2. Analytical approaches of each tumor sample. Table S3. Table S3. 52 out of 226 unique deletions in BrM with a q-value less than 0.1. Table S4. 5 out of 15 unique amplifications in BrM with a q-value less than 0.1. Table S5. Proteomic analysis of LC-BrMs and paired primary lung cancer (processed data). Table S6. Metabolite analysis of LC-BrMs and paired primary lung cancer (processed data). Table S7. Metabolite analysis of LC-BrMs PDOs treated with DMSO or gamitrinib.